Integrating Cardiovascular Screening in Lung Cancer Screening.

Mohammad Mozafary¹, Maryam Rezaeifar², Morteza Naghavi¹, Ella A Kazerooni³, Arthur E Stillman⁴, Paolo Raggi²

¹HeartLung.AI, Houston, TX, USA.

²Department of Medicine and Division of Cardiology, University of Alberta, Edmonton, AB, Canada.

³Departments of Radiology and Internal Medicine, Michigan Medicine/University of Michigan Medical School, Ann Arbor, MI.

⁴Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.

PubMed DOI

Abstract

Cardiovascular risk assessment is a natural extension of lung cancer screening (LCS) because individuals eligible for low-dose computed tomography often carry a high burden of cardiovascular risk, and cardiovascular disease remains a major competing cause of morbidity and mortality. The same examination can provide clinically relevant cardiovascular information, particularly through coronary arter…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.